Evidence map›Paper›PMID 38378775›Full record

ArticleNature communications2024

Imputation of plasma lipid species to facilitate integration of lipidomic datasets.

Aleksandar Dakic, Jingqin Wu, Tingting Wang, Kevin Huynh, Natalie Mellett, Thy Duong, Habtamu B Beyene, Dianna J Magliano, Jonathan E Shaw, Melinda J Carrington and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Aleksandar DakicBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.ORCID http://orcid.org/0009-0004-1110-454X
Jingqin WuBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.ORCID http://orcid.org/0000-0002-2052-3875
Tingting WangBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.
Kevin HuynhBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.ORCID http://orcid.org/0000-0001-6170-2207
Natalie MellettBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.
Thy DuongBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.ORCID http://orcid.org/0000-0002-2521-078X
Habtamu B BeyeneBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.ORCID http://orcid.org/0000-0001-7075-6629
Dianna J MaglianoBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.ORCID http://orcid.org/0000-0002-9507-6096
Jonathan E ShawBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.ORCID http://orcid.org/0000-0002-6187-2203
Melinda J CarringtonBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.
Michael InouyeBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.
Jean Y YangSchool of Mathematics and Statistics, The University of Sydney, Camperdown, NSW, 2006, Australia.ORCID http://orcid.org/0000-0002-5271-2603
Gemma A FigtreeKolling Institute of Medical Research, The University of Sydney, St Leonards, NSW, 2065, Australia.
Joanne E CurranDepartment of Human Genetics and South Texas Diabetes and Obesity Institute, School of Medicine at University of Texas Rio Grande Valley, Brownsville, TX, USA.ORCID http://orcid.org/0000-0002-6898-155X
John BlangeroDepartment of Human Genetics and South Texas Diabetes and Obesity Institute, School of Medicine at University of Texas Rio Grande Valley, Brownsville, TX, USA.ORCID http://orcid.org/0000-0001-6250-5723
John SimesNational Health and Medical Research Council of Australia (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
LIPID Study Investigators
Corey GilesBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia. corey.giles@baker.edu.au.ORCID http://orcid.org/0000-0002-6050-1259
Peter J MeikleBaker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia. peter.meikle@baker.edu.au.ORCID http://orcid.org/0000-0002-2593-4665

Funding

PEDIGREE ANALYSIS OF LIPOPROTEIN PHENOTYPESP01HL045522 · NHLBI · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ALMASY, LAURA A. · 1991 to 2012
$27.6M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ESCAMILLA, MICHAEL A · 1985 to 2008
$23.1M
Whole Genome Sequencing to Identify Causal Genetic Variants Influencing CVD RiskR01HL113323 · NHLBI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI BLANGERO, JOHN, CURRAN, JOANNE E. · 2012 to 2016
$8.2M
Genetics of Brain Structure and FunctionR01MH078111 · NIMH · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BLANGERO, JOHN · 2006 to 2014
$4.5M
Genetics of Brain Structure and FunctionR01MH078143 · NIMH · YALE UNIVERSITY · PI GLAHN, DAVID C · 2006 to 2014
$4.3M
Identification of the Exposome in Fatty Liver Disease in Mexican American Families Using Genetic CorrectionR01MD012564 · NIMHD · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI BLANGERO, JOHN, CLARKE, GEOFFREY DAVID · 2018 to 2022
$3.7M
Genetics of Brain Structure and Function: Genome-Wide AssociationR01MH083824 · NIMH · YALE UNIVERSITY · PI GLAHN, DAVID C · 2008 to 2013
$3.3M
Assessing the Influence of the Human Lipidome on Risk of Diabetes in a Minority PopulationR01DK127636 · NIDDK · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CURRAN, JOANNE E., MEIKLE, PETER JOHN · 2021 to 2024
$2.7M
Genetic Determinants of Lipidomic Variation and Their Role in CVD RiskR01HL140681 · NHLBI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CURRAN, JOANNE E., MEIKLE, PETER JOHN · 2018 to 2021
$2.4M
NCRR NIH HHS M01 RR001346NHLBI NIH HHS P01 HL045522NHLBI NIH HHS R01 HL113323NHLBI NIH HHS R01 HL140681NIDDK NIH HHS R01 DK127636NIMHD NIH HHS R01 MD012564NIMH NIH HHS R01 MH078111NIMH NIH HHS R01 MH078143NIMH NIH HHS R01 MH083824
6 · The paper itself

Abstract

Recent advancements in plasma lipidomic profiling methodology have significantly increased specificity and accuracy of lipid measurements. This evolution, driven by improved chromatographic and mass spectrometric resolution of newer platforms, has made it challenging to align datasets created at different times, or on different platforms. Here we present a framework for harmonising such plasma lipidomic datasets with different levels of granularity in their lipid measurements. Our method utilises elastic-net prediction models, constructed from high-resolution lipidomics reference datasets, to predict unmeasured lipid species in lower-resolution studies. The approach involves (1) constructing composite lipid measures in the reference dataset that map to less resolved lipids in the target dataset, (2) addressing discrepancies between aligned lipid species, (3) generating prediction models, (4) assessing their transferability into the targe dataset, and (5) evaluating their prediction accuracy. To demonstrate our approach, we used the AusDiab population-based cohort (747 lipid species) as the reference to impute unmeasured lipid species into the LIPID study (342 lipid species). Furthermore, we compared measured and imputed lipids in terms of parameter estimation and predictive performance, and validated imputations in an independent study. Our method for harmonising plasma lipidomic datasets will facilitate model validation and data integration efforts.

Indexed as

LipidomicsPlasmaHumansLipidsMass SpectrometryLipids

Identifiers

PMID38378775
PMCPMC10879118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.